The Patent Finder

Calyx Therapeutics, Inc.

Also on record
Records under this name other than patents Calyx Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Calyx Therapeutics, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,407,978Heterocyclic analogs of diphenylethylene compounds
Formerly held
Lapsed on the fee record
Ended Aug 5, 2016 · USPTO record
Lapsed on the fee recordEnded Aug 5, 2016USPTO record
US 7,323,496Compounds for treatment of inflammation, diabetes and related disorders
Formerly held
Lapsed on the fee record
Ended Jan 29, 2016 · USPTO record
Lapsed on the fee recordEnded Jan 29, 2016USPTO record
US 7,202,366Heterocyclic analogs of diphenylethylene compounds
Formerly held
Lapsed on the fee record
Ended Apr 10, 2015 · USPTO record
Lapsed on the fee recordEnded Apr 10, 2015USPTO record
US 7,105,552Heterocyclic analogs of diphenylethylene compounds
Formerly held
Lapsed on the fee record
Ended Sep 12, 2014 · USPTO record
Lapsed on the fee recordEnded Sep 12, 2014USPTO record
US 7,718,682Heterocyclic analogs of diphenylethylene compounds
Formerly held
Lapsed on the fee record
Ended May 18, 2014 · USPTO record
Lapsed on the fee recordEnded May 18, 2014USPTO record
US 6,331,633Heterocyclic analogs of diphenylethylene compounds
Formerly held
Lapsed on the fee record
Ended Dec 18, 2013 · USPTO record
Lapsed on the fee recordEnded Dec 18, 2013USPTO record
US 6,245,814Diphenylethylene compounds
Formerly held
Lapsed on the fee record
Ended Jun 12, 2013 · USPTO record
Lapsed on the fee recordEnded Jun 12, 2013USPTO record
US 6,855,732Compounds to treat diabetes and associated conditions
Formerly held
Lapsed on the fee record
Ended Feb 15, 2013 · USPTO record
Lapsed on the fee recordEnded Feb 15, 2013USPTO record
US 6,852,695Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
Formerly held
Lapsed on the fee record
Ended Feb 8, 2013 · USPTO record
Lapsed on the fee recordEnded Feb 8, 2013USPTO record
US 6,127,338Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
Formerly held
Lapsed on the fee record
Ended Oct 3, 2012 · USPTO record
Lapsed on the fee recordEnded Oct 3, 2012USPTO record
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited